In this Expert Perspectives video, Andrew Blauvelt, MD, MBA, discusses emerging efficacy data for targeted oral psoriasis therapies and how clinicians can interpret head-to-head t ...

Without a formal staging system, advanced basal cell carcinoma is defined by the interplay of tumor size, anatomic site, depth, histology, and host factors that may not be apparent on initial biopsy.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

ET-02 showed significant hair growth, surpassing minoxidil's results in a shorter timeframe, with no safety concerns observed. The drug targets stem cell biology, correcting defects causing hair loss, ...

Celltrion USA announced on October 5, 2026, that Omlyclo (omalizumab-igec), the first FDA-approved interchangeable biosimilar ...

From next-generation oral therapies and long-term disease control to precision medicine, EADV 2026 highlighted a dermatology landscape increasingly focused on deeper, durable, and individualized ...

Patient-reported burden improved in adults, with DLQI dropping from 14.5 to 7.9 and itch/pain numerical rating scales ...

Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...

Phase 3 ABTECT-Maintenance will report 44-week efficacy and safety of obefazimod in moderately to severely active UC using a randomized, double-blind, placebo-controlled design. Subset analyses will ...

Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy. Emma ...

IL-31 receptor targeting may differentiate nemolizumab by impacting pruritus-driven neuroimmune signaling while also modulating inflammation and epidermal barrier disruption. Correlative analyses ...